Fetuin-A (AHSG) Human
| Type: | Native | ||
|---|---|---|---|
| Tag: | Tagless | ||
| Source: | Human plasma | ||
| Species: | Human | ||
| Other names: | AHSG | ||
| Cat. No.: | RD172037100 | ||
| Size: | 0.1 mg | | | |
| Cat. No.: | RD172037100+ | ||
| Size: | 10 x 0.1 mg | | | |
| Files: | Datasheet PDF MSDS | ||
| Legend: | new product discount |
temporarily out of stock order in advance |
|
Description
The Human Fetuin is purified from the human plasma.
Source
Human plasma
Purity
>95%
SDS-PAGE gel
|
12% SDS-PAGE separation of Human Fetuin |
Formulation
Filtered (0,4 μm) and lyophilized in 0.5 mg/mL in PBS pH7.4
Reconstitution
Add deionized water to prepare a working stock solution of approximately 0.5 mg/mL and let the lyophilized pellet dissolve completely. Product is not sterile! Please filter the product by an appropriate sterile filter before using it in the cell culture.
Storage, Stability/Shelf Life
Store lyophilized protein at –20°C. Lyophilized protein remains stable until the expiry date when stored at –20°C. Aliquot reconstituted protein to avoid repeated freezing/thawing cycles and store at –80°C for long term storage. Reconstituted protein can be stored at 4°C for a limited period of time; it does not show any change after two weeks at 4°C.
Quality Control Test
BCA to determine quantity of the protein.
SDS PAGE to determine purity of the protein.
Applications
ELISA, Western blotting
Note
This product is intended for research use only.
Introduction to the Molecule
Fetuin-A (AHSG), a 59 kDa glycoprotein, consisting of two cystatin-like domains and a smaller unrelated domain, is predominantly sinthetized in liver . It is secreted into the blood stream and deposited as a noncollagenous protein in mineralized bones and teeth. Fetuin-A occurs in high serum concentrations during foetal life, whereas its level declines following infection, inflamatory and malignancy. Fetuin-A acts as an important circulating inhibitor of ectopic calcification, frequent complication of many degenerative diseases. Low serum level of Fetuin-A is associated with vascular and valvular calcification, atherosclerosis, malnutrition and higher cardiovascular mortality in chronic renal failure, liver cancer and liver cirrhosis patients on long-term dialysis. AHSG protein represents a natural inhibitor of tyrosinase kinase activity of the insulin receptor. It may play a significant role in regulating postprandial glucose disposal, insulin sensitivity, weight gain, and fat accumulation. The serum and bone-resident Fetuin-A binds to transforming growth factor- β and blocks TGF-β binding to cell surface receptors.
References
- Arnaud P, Kalabay L. Alpha2-HS glycoprotein: a protein in search of a function. Diabetes Metab Res Rev. 2002 Jul-Aug; 18(4): 311-4. Review.
- Ketteler M, Bongartz P, Westenfeld R, Wildberger JE, Mahnken AH, Bohm R, Metzger T, Wanner C, Jahnen-Dechent W, Floege J. Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study. Lancet. 2003 Mar 8; 361(9360): 827-33.
- Jersmann HP, Dransfield I, Hart SP. Fetuin/alpha2-HS glycoprotein enhances phagocytosis of apoptotic cells and macropinocytosis by human macrophages. Clin Sci (Lond). 2003 Sep; 105(3): 273-8.
- Schafer C, Heiss A, Schwarz A, Westenfeld R, Ketteler M, Floege J, Muller-Esterl W, Schinke T, Jahnen-Dechent W. The serum protein alpha 2-Heremans-Schmid glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcification. J Clin Invest. 2003 Aug; 112(3): 357-66.
- Denecke B, Graber S, Schafer C, Heiss A, Woltje M, Jahnen-Dechent W. Tissue distribution and activity testing suggest a similar but not identical function of fetuin-B and fetuin-A. Biochem J. 2003 Nov 15; 376(Pt 1): 135-45.
Shopping cart
Your cart is empty.
new product
discount
temporarily out of stock
order in advance